Artelo Biosciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended August 31, 2019; filed November 25, 2019. This is an annual report, not a calendar fourth-quarter filing. Artelo is a clinical-stage biopharmaceutical company developing therapies that modulate the endocannabinoid system. It had no product revenue and no approved products.
Financial performance and liquidity
| Metric | FY2019 / August 31, 2019 | FY2018 / August 31, 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.210 million | $2.343 million |
| Loss from operations | $3.210 million | $2.343 million |
| Net loss | $2.172 million | $2.343 million |
| Cash and cash equivalents | $4.424 million | $0.337 million |
| Total assets | $6.483 million | $0.397 million |
| Total liabilities | $1.022 million | $0.532 million |
| Stockholders’ equity (deficit) | $5.461 million | $(0.135) million |
| Working capital | $3.421 million | $(0.136) million |
| Cash used in operating activities | $2.793 million | $1.610 million |
| Cash used in investing activities | $1.501 million | $0.001 million |
| Cash provided by financing activities | $8.377 million | $1.388 million |
No operating margin is meaningful because the company had no revenue. The filing does not identify material conventional borrowings; reported liabilities include $348,863 of accounts payable and accrued liabilities, $639,417 of stock payable, $29,501 of derivative liability, and $3,732 due to a related party.
Material changes and notable items
- Operating expenses increased $866,040, mainly from higher professional fees and general and administrative costs; research and development expense decreased by $157,862.
- Net loss narrowed by $171,315, despite the higher operating loss. The result included $1.006 million of income from a change in fair value of derivative liabilities, an unusual non-operating item.
- Cash rose primarily through equity financing. The company reported $8.376 million of proceeds from common-stock issuance, including a June 2019 public offering that generated approximately $8.0 million gross before underwriting discounts and offering expenses.
- In July 2019, Artelo paid $1.5 million and recorded $539,417 of stock payable to exercise an exclusive worldwide license for ART27.13; the $2.039 million total was capitalized as an intangible asset.
- The company effected a one-for-eight reverse stock split in June 2019 and began trading its common stock and warrants on Nasdaq in June. Financing included substantial warrant issuance, creating potential future dilution.
Outlook, risks, and contingencies
- Management and the independent auditor reported substantial doubt about the company’s ability to continue as a going concern. Artelo has recurring losses, no revenue, and expects to need additional capital; management gave no assurance that financing will be available on acceptable terms or at all.
- ART27.13 was planned for a Phase 1b/2a cancer-related anorexia study, then anticipated to begin in the second quarter of 2020 subject to manufacturing and regulatory steps, with initial data expected by year-end. ART26.12 was in late preclinical development, with cancer clinical studies anticipated in 2021. ART12.11, a CBD cocrystal, remained preclinical. These are forward-looking expectations, not financial guidance.
- Key risks include clinical and regulatory uncertainty, financing needs, dependence on licensors and contractors, protection and maintenance of intellectual property, controlled-substance regulation, competition, and dependence on a very small team. The NEOMED license also carries potential milestone payments of up to $200 million and mid-to-high single-digit royalties on annual net sales.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at year-end, citing inadequate segregation of duties and management concentration in one individual. The auditor did not attest to internal-control effectiveness.
- The filing reported no pending material legal proceedings and no material off-balance-sheet arrangements. No financial guidance was provided.
Important facts for investors to verify
- Confirm the company’s cash runway and current financing needs against its going-concern warning; year-end cash does not remove the disclosed substantial doubt.
- Reconcile share counts: the cover reports 3,426,276 shares outstanding as of November 21, 2019, while the share-capital discussion reports 3,426,726; year-end shares were 3,353,616.
- Check the cash-flow discussion for apparent transcription inconsistencies: one passage gives net loss as $2,712,176, whereas the audited statements report $2,172,176; the MD&A cash-flow table also labels comparative periods as 2018 and 2017, while the audited cash-flow statement compares 2019 and 2018.
- Assess the quality of FY2019 earnings: the reported net loss was reduced by the $1.006 million derivative fair-value gain, while operating loss increased.
- Track the timing, funding, manufacturing, regulatory progress, and clinical results for ART27.13, ART26.12, and ART12.11, as well as potential dilution from outstanding warrants and options.